stockrow
Friday 6 November 2026
Export NVS’s income statement to Excel — free account
Novartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
162.40
0.47
+0.29%
Follow NVS
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
5 | 5 | 5 | 8 |
+8 more TTM periods Free account |
| 24.37% | 30.37% | 34.98% | 30.84% | ||
| 8.94% | 11.27% | 12.39% | 13.12% | ||
ROIC |
12.05% | 13.14% | 13.97% | 16.10% | |
Return on Tangible Assets |
146.57% | 202.88% | 229.90% | 100.14% | |
Average Days of Receivables |
63.39 | 63.44 | 61.95 | 58.88 | |
Free Cash Flow per Share |
7.46 | 7.97 | 8.45 | 7.95 | |
Free Cash Flow |
14,145.00 | 15,177.00 | 16,128.00 | 15,421.00 | |
Capital Expenditures |
(3,180.00) | (3,216.00) | (3,047.00) | (3,723.00) | |
| Other line items | |||||
Cash ROIC |
15.23% | 15.69% | 17.73% | 16.82% | |
Accounts Receivable Turnover |
6.06 | 5.96 | 6.17 | 6.79 | |
Accounts Payable Turnover |
3.27 | 3.27 | 3.25 | 3.03 | |
Inventory Turnover |
2.30 | 2.29 | 2.30 | 2.28 | |
Average Days of Payables |
107.64 | 108.54 | 113.24 | 118.73 | |
Days of Inventory on Hand |
154.85 | 158.55 | 164.70 | 167.03 | |
Tax Rate |
(0.21) | (0.18) | (0.14) | (0.15) | |
Research and Development Expense of Revenue |
24.23% | 20.63% | 20.46% | 19.76% | |
Selling, General and Administrative Expense of Revenue |
22.49% | 23.16% | 23.56% | 23.38% | |
Share Based Compensation of Revenue |
1.98% | 2.01% | 2.01% | 1.93% | |
Interest Coverage |
9.16 | 12.30 | 14.15 | 15.42 | |
Operating CF/Net income |
1.73 | 1.44 | 1.42 | 1.37 | |
Depreciation/Fixed assets |
0.72 | 0.51 | 0.50 | 0.49 | |
Capex/Depreciation |
(0.41) | (0.59) | (0.58) | (0.71) | |
Revenue per Share |
30.26 | 29.76 | 29.64 | 29.23 | |
Operating CF per Share |
9.14 | 9.66 | 10.04 | 9.87 | |
Capex per Share |
(1.68) | (1.69) | (1.60) | (1.92) | |
Capex to Sales |
0.06 | 0.06 | 0.05 | 0.07 |
Columns are period end dates · fundamentals updated 2 Nov 2026